# Cancer Molecular Profile

Tumor molecular profiles for various cancer types

## About

This cancer-molecular-profile repository lists tumor molecular profiles for various cancer types, including rare fractions.

We create the list of gene variants and biomarkers by referring to public databases as follows:

- COSMIC
- GDC Data Portal (TCGA)
- My Cancer Genome

To make the list more objective, we also referred to literature, especially comprehensive papers summarizing NGS analysis, searched by PubMed for each cancer type. We reflected these in the list of gene variants and biomarkers.

We define the following two sections as molecular profiles for each tumor type:

- `Representative Gene Variants or Biomarkers`: Frequently present in the  specified tumor type and significant for the specific molecular subtype of it
- `Other Gene Variants or Biomarkers`: Present in some of the specified tumor types and characterize the molecular subtype

## Profiles

Total: 114 cases

| Tissue | Subtype | Representative Gene Variants or Biomarkers | Other Gene Variants or Biomarkers |
| --- | --- | --- | --- |
| Adrenal Gland | Pheochromocytoma | SDHB loss | TP53 truncation, ATRX truncation, HRAS p.Q61X |
| Adrenal Gland | Pheochromocytoma | RET p.C634R p.M918T | TP53 truncation, ATRX truncation |
| Biliary Tract | Cholangiocarcinoma | IDH1 p.R132C, TP53 truncation | CDKN2A loss, CDKN2B loss, MTAP loss, ARID1A truncation, BAP1 loss |
| Biliary Tract | Cholangiocarcinoma | IDH2 p.R172G/K/M/S/W, TP53 truncation | BAP1 truncation loss, CDKN2A loss, CDKN2B loss, MTAP loss, ARID1A truncation |
| Biliary Tract | Cholangiocarcinoma | ERBB2 amplification, TP53 truncation | BAP1 truncation, CDKN2A loss, CDKN2B loss, MTAP loss, ARID1A truncation |
| Biliary Tract | Cholangiocarcinoma | FGFR2-BICC1 fusion, TP53 truncation | BAP1 truncation, CDKN2A loss, CDKN2B loss, MTAP loss, ARID1A truncation |
| Biliary Tract | Cholangiocarcinoma | KRAS p.G12X, TP53 truncation | BAP1 truncation, CDKN2A loss, CDKN2B loss, MTAP loss, ARID1A truncation |
| Biliary Tract | Gallbladder Cancer | ERBB2 amplification p.S310F/Y, TP53 truncation, CDKN2A loss, CDKN2B loss, SMAD4 loss truncation | ARID1A truncation, CCNE1 amplification, PIK3CA p.E542K p.E545K p.H1047R |
| Biliary Tract | Gallbladder Cancer | ERBB2 amplification p.S310F/Y, MDM2 amplification, CDKN2A loss, CDKN2B loss, SMAD4 loss truncation | ARID1A truncation, CCNE1 amplification, PIK3CA p.E542K p.E545K p.H1047R |
| Biliary Tract | Gallbladder Cancer | KRAS p.G12X, TP53 truncation, CDKN2A loss, CDKN2B loss, SMAD4 loss truncation | ARID1A truncation, CCNE1 amplification, PIK3CA p.E542K p.E545K p.H1047R |
| Bladder | Urothelial Carcinoma | FGFR3 p.S249C p.R248C | TP53 truncation, TERT c.-124C>T, PIK3CA p.E545K p.H1047R, ARID1A truncation, RB1 truncation, BRAF p.V600E/K |
| Bladder | Urothelial Carcinoma | FGFR3-TACC3 fusion | TP53 truncation, TERT c.-124C>T, PIK3CA p.E545K p.H1047R, ARID1A truncation, RB1 truncation, BRAF p.V600E/K |
| Bladder | Urothelial Carcinoma | CDKN2A loss, CDKN2B loss | TP53 truncation, TERT c.-124C>T, PIK3CA p.E545K p.H1047R, ARID1A truncation, RB1 truncation, BRAF p.V600E/K |
| Bone | Osteosarcoma | TP53 loss, RB1 loss | BRCA1 truncation, PTEN truncation, MYC amplification, CCNE1 amplification, CDKN2A loss, CDKN2B loss |
| Bowel | Colorectal Adenocarcinoma | APC truncation, KRAS p.G12X, SMAD4 truncation, TP53 truncation | EGFR amplification, ERBB2 amplification p.R678Q, PTEN truncation |
| Bowel | Colorectal Adenocarcinoma | APC truncation, NRAS p.Q61X, SMAD4 truncation, TP53 truncation | EGFR amplification, ERBB2 amplification p.R678Q, PTEN truncation |
| Bowel | Colorectal Adenocarcinoma | APC truncation, BRAF p.V600E/K, SMAD4 truncation, TP53 truncation | EGFR amplification, ERBB2 amplification p.R678Q, PTEN truncation |
| Bowel | Colorectal Adenocarcinoma | MLH1 truncation, TMB-High, MSI-High, APC truncation, SMAD4 truncation, TP53 truncation | BRAF p.V600E/K |
| Bowel | Colorectal Adenocarcinoma | MSH2 truncation, TMB-High, MSI-High, APC truncation, SMAD4 truncation, TP53 truncation | BRAF p.V600E/K |
| Bowel | Colorectal Adenocarcinoma | MSH6 truncation, TMB-High, MSI-High, APC truncation, SMAD4 truncation, TP53 truncation | BRAF p.V600E/K |
| Bowel | Colorectal Adenocarcinoma | PMS2 truncation, TMB-High, MSI-High, APC truncation, SMAD4 truncation, TP53 truncation | BRAF p.V600E/K |
| Bowel | Colorectal Adenocarcinoma | EPCAM truncation, APC truncation, KRAS p.G12X, SMAD4 truncation, TP53 truncation | EGFR amplification, ERBB2 amplification p.R678Q |
| Bowel | Colorectal Adenocarcinoma | MUTYH truncation, APC truncation, KRAS p.G12X, SMAD4 truncation, TP53 truncation | EGFR amplification, ERBB2 amplification p.R678Q |
| Brain | Astrocytoma, IDH-mutant | IDH1 p.R132C/G/H/L/S, TP53 truncation | PTEN truncation, BRAF p.V600E, EGFR amplification |
| Brain | Astrocytoma, IDH-mutant | IDH2 p.R172K/S, TP53 truncation | PTEN truncation, BRAF p.V600E, EGFR amplification |
| Brain | Atypical Teratoid/Rhabdoid Tumor | SMARCB1 loss | TP53 truncation |
| Brain | Diffuse Midline Glioma, H3 K27-altered | H3-3A p.K28M, TP53 truncation | PIK3CA p.E542K p.E545K p.H1047R, ATRX truncation |
| Brain | Glioblastoma, IDH-wildtype | TP53 truncation, EGFR amplification, PTEN truncation | NF1 truncation, RB1 truncation |
| Brain | Glioblastoma, IDH-wildtype | TP53 truncation, EGFR amplification, PIK3CA p.E542K p.E545K p.H1047R | NF1 truncation, RB1 truncation |
| Brain | Glioblastoma, IDH-wildtype | TERT c.-124C>T, TP53 truncation | PIK3CA p.E542K p.E545K p.H1047R, BRAF p.V600E, EGFR amplification, RB1 truncation |
| Brain | Glioblastoma, IDH-wildtype | TERT c.-124C>T, TP53 truncation | PTEN truncation, NF1 truncation, EGFR amplification, RB1 truncation |
| Brain | Glioblastoma, IDH-wildtype | ATRX truncation, TP53 truncation | PTEN truncation, NF1 truncation, EGFR amplification, RB1 truncation |
| Brain | Medulloblastoma | CTNNB1 p.S33A/C/F/Y p.S37A/F/Y | TP53 truncation, DDX3X p.T275M p.G302V p.R326C p.R351W p.M380I, KMT2D truncation, CREBBP truncation |
| Brain | Medulloblastoma | PTCH1 truncation | TP53 truncation, DDX3X p.T275M p.G302V p.R326C p.R351W p.M380I, TERT c.-124C>T, KMT2D truncation, CREBBP truncation |
| Brain | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | IDH1 p.R132H/C/G, 1p loss, 19q loss | TP53 truncation, ARID1A truncation, PIK3CA p.E542K p.E545K p.H1047R, NOTCH1 truncation, CIC p.R202W p.R215W/Q truncation |
| Brain | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | IDH2 p.R172K/S, 1p loss, 19q loss | TP53 truncation, ARID1A truncation, PIK3CA p.E542K p.E545K p.H1047R, NOTCH1 truncation, CIC p.R202W p.R215W/Q truncation |
| Breast | Breast Invasive Ductal Carcinoma | ESR1 p.Y537S p.D538G amplification, PIK3CA p.E545K p.H1047R | TP53 truncation, MAP3K1 truncation, ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, CDKN2A loss, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | ERBB2 amplification p.S310F, TP53 truncation | FGFR1 amplification, MAP3K1 truncation, PTEN truncation, KMT2C truncation, CDKN2A loss, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | TP53 truncation, ATM truncation | ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | TP53 truncation, CHEK2 truncation, HRD-High | ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | TP53 truncation, BRCA1 truncation, HRD-High | ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | TP53 truncation, BRCA2 truncation, HRD-High | ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, RB1 loss |
| Breast | Breast Invasive Ductal Carcinoma | TP53 truncation, PALB2 truncation, HRD-High | ERBB2 amplification p.S310F, PTEN truncation, KMT2C truncation, RB1 loss |
| Breast | Breast Invasive Lobular Carcinoma | CDH1 truncation, PIK3CA p.E545K p.H1047R | TP53 truncation, RUNX1 truncation, TBX3 truncation, PTEN loss |
| Esophagus | Squamous Cell Carcinoma | TP53 truncation | NFE2L2 p.R34G/L p.E79K/Q, KMT2D truncation, PTEN truncation |
| Esophagus | Squamous Cell Carcinoma | TP53 truncation | NOTCH1 truncation, KMT2D truncation, PTEN truncation |
| Esophagus | Squamous Cell Carcinoma | TP53 truncation | CDKN2A truncation, KMT2D truncation, PTEN truncation |
| Kidney | Renal Cell Carcinoma | VHL truncation loss | TP53 truncation |
| Kidney | Wilms Tumor | WT1 loss | TP53 truncation, CTNNB1 p.T41A p.S45F |
| Lung | Lung Adenocarcinoma | EGFR p.L858R exon 19 deletion exon 20 insertion, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Lung Adenocarcinoma | KRAS p.G12X, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Lung Adenocarcinoma | MET exon 14 skipping, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Lung Adenocarcinoma | EML4-ALK fusion, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Lung Adenocarcinoma | KIF5B-RET fusion, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Lung Adenocarcinoma | GOPC-ROS1 fusion, STK11 truncation, TP53 truncation | KEAP1 loss-of-function missense mutation truncation, SETD2 truncation, ARID1A truncation |
| Lung | Small Cell Lung Cancer | RB1 truncation, TP53 truncation |  |
| Lung | Squamous Cell Carcinoma | NFE2L2 p.R34G p.R34L p.E79K p.E79Q, TP53 truncation | CDKN2A loss, PIK3CA p.E545K p.H1047R amplification, KEAP1 loss-of-function missense mutation truncation |
| Ovary | Clear Cell Ovarian Cancer | ARID1A truncation, PIK3CA p.E545K p.H1047R | TP53 truncation |
| Ovary | High-Grade Serous Ovarian Cancer | TP53 truncation, HRD-High | BRCA1 truncation |
| Ovary | High-Grade Serous Ovarian Cancer | TP53 truncation, HRD-High | BRCA2 truncation |
| Ovary | Low-Grade Serous Ovarian Cancer | KRAS p.G12X |  |
| Ovary | Low-Grade Serous Ovarian Cancer | NRAS p.Q61X |  |
| Ovary | Low-Grade Serous Ovarian Cancer | BRAF p.V600E/K |  |
| Pancreas | Intraductal Papillary Mucinous Neoplasm | KRAS p.G12X, TP53 truncation, GNAS p.R201C/H |  |
| Pancreas | Pancreatic Adenocarcinoma | KRAS p.G12X, TP53 truncation | CDKN2A loss, CDKN2B loss, MTAP loss |
| Pancreas | Pancreatic Adenocarcinoma | KRAS p.G12X, TP53 truncation, ATM truncation | CDKN2A loss, CDKN2B loss, MTAP loss |
| Pancreas | Pancreatic Adenocarcinoma | KRAS p.G12X, TP53 truncation, BRCA1 truncation | CDKN2A loss, CDKN2B loss, MTAP loss |
| Pancreas | Pancreatic Adenocarcinoma | KRAS p.G12X, TP53 truncation, BRCA2 truncation | CDKN2A loss, CDKN2B loss, MTAP loss |
| Peritoneum | Mesothelioma | BAP1 loss, TP53 truncation | NF2 truncation loss |
| Pleura | Mesothelioma | BAP1 loss, TP53 truncation | NF2 truncation loss |
| Prostate | Adenocarcinoma | AR amplification, TP53 truncation, PTEN truncation | PIK3CA p.E545K p.H1047R, MYC amplification, SPOP p.F133C/L/V, RB1 loss |
| Prostate | Adenocarcinoma | ATM truncation | HRD-High, AR amplification, TP53 truncation, PIK3CA p.E545K p.H1047R, PTEN truncation, MYC amplification, SPOP p.F133C/L/V, RB1 loss |
| Prostate | Adenocarcinoma | BRCA1 truncation | HRD-High, AR amplification, TP53 truncation, PIK3CA p.E545K p.H1047R, PTEN truncation, MYC amplification, SPOP p.F133C/L/V, RB1 loss |
| Prostate | Adenocarcinoma | BRCA2 truncation | HRD-High, AR amplification, TP53 truncation, PIK3CA p.E545K p.H1047R, PTEN truncation, MYC amplification, SPOP p.F133C/L/V, RB1 loss |
| Prostate | Adenocarcinoma | CDK12 truncation | HRD-High, AR amplification, TP53 truncation, PIK3CA p.E545K p.H1047R, PTEN truncation, MYC amplification, SPOP p.F133C/L/V, RB1 loss |
| Prostate | Adenocarcinoma | TMPRSS2-ERG fusion, TP53 truncation, PTEN truncation | AR amplification, PIK3CA p.E545K p.H1047R, MYC amplification, RB1 loss, SPOP p.F133C/L/V |
| Salivary Gland | Adenoid Cystic Carcinoma | MYB-NFIB fusion | TP53 truncation, NOTCH1 truncation |
| Salivary Gland | Mucoepidermoid Carcinoma | HRAS p.G12V, PIK3CA p.E542K p.E545K p.H1047R | TP53 truncation, CDKN2A loss, CDKN2B loss |
| Salivary Gland | Salivary Duct Carcinoma | ERBB2 amplification, CDK12 amplification, TP53 truncation | CDKN2A loss |
| Salivary Gland | Salivary Duct Carcinoma | HRAS p.Q61X, TP53 truncation | PIK3CA p.E542K p.E545K p.H1047R, CDKN2A loss |
| Salivary Gland | Salivary Duct Carcinoma | NF1 truncation, TP53 truncation | CDKN2A loss |
| Skin | Melanoma | BRAF p.V600E/K | CDKN2A loss, CDKN2B loss, MTAP loss |
| Skin | Melanoma | NRAS p.Q61X | CDKN2A loss, CDKN2B loss, MTAP loss |
| Skin | Melanoma | KIT p.L576P p.K642E | CDKN2A loss, CDKN2B loss, MTAP loss |
| Soft Tissue | Dedifferentiated Liposarcoma | MDM2 amplification, CDK4 amplification |  |
| Soft Tissue | Ewing Sarcoma | EWSR1-FLI1 fusion | TP53 truncation, CDKN2A loss, STAG2 truncation |
| Soft Tissue | Gastrointestinal Stromal Tumor | KIT p.W557_K558del p.V559G p.L576P |  |
| Soft Tissue | Leiomyosarcoma | TP53 loss, RB1 loss | ATRX truncation, PTEN loss truncation, MAP2K4 amplification |
| Soft Tissue | Paraganglioma | SDHB loss | TP53 truncation, ATRX truncation |
| Soft Tissue | Rhabdomyosarcoma | PAX3-FOXO1 fusion | MYCN amplification, CDK4 amplification, 11p15 loss |
| Soft Tissue | Rhabdomyosarcoma | PAX7-FOXO1 fusion | MYCN amplification, CDK4 amplification, 11p15 loss |
| Soft Tissue | Rhabdomyosarcoma | NRAS p.Q61X, 11p15 loss | TP53 loss |
| Soft Tissue | Rhabdomyosarcoma | FGFR4 p.V550E/L/M, 11p15 loss | TP53 loss |
| Soft Tissue | Synovial Sarcoma | SS18-SSX2 fusion | CTNNB1 p.S33A/Y/C p.S37A/F/Y p.T41A p.S45F, ATM truncation |
| Stomach | Diffuse Type Stomach Adenocarcinoma | CDH1 truncation, RHOA p.Y42C/S | CLDN18-ARHGAP26 fusion |
| Stomach | Intestinal Type Stomach Adenocarcinoma | PIK3CA p.E545K p.H1047R, ARID1A truncation, CD274 amplification, ERBB2 amplification | PTEN truncation |
| Stomach | Intestinal Type Stomach Adenocarcinoma | PIK3CA p.E545K p.H1047R, ARID1A truncation, CD274 amplification, EGFR amplification | PTEN truncation |
| Stomach | Intestinal Type Stomach Adenocarcinoma | MLH1 truncation, TMB-High, MSI-High | ARID1A truncation, PIK3CA p.E545K p.H1047R, PTEN truncation, KRAS p.G12X, RNF43 truncation, TP53 truncation |
| Stomach | Intestinal Type Stomach Adenocarcinoma | KRAS amplification, TP53 truncation | CCNE1 amplification, CCND1 amplification |
| Stomach | Intestinal Type Stomach Adenocarcinoma | ERBB2 amplification, TP53 truncation | CCNE1 amplification, CCND1 amplification |
| Stomach | Intestinal Type Stomach Adenocarcinoma | EGFR amplification, TP53 truncation | CCNE1 amplification, CCND1 amplification |
| Stomach | Intestinal Type Stomach Adenocarcinoma | PIK3CA amplification, TP53 truncation | CCNE1 amplification, CCND1 amplification |
| Thymus | Thymic carcinoma | TP53 truncation, CDKN2A loss, CDKN2B loss |  |
| Thyroid | Anaplastic Carcinoma | BRAF p.V600E, TP53 truncation | CDKN2A loss, CDKN2B loss, PTEN truncation |
| Thyroid | Follicular Carcinoma | NRAS p.Q61X | TP53 truncation |
| Thyroid | Follicular Carcinoma | PAX8-PPARG fusion | TP53 truncation |
| Thyroid | Papillary Carcinoma | BRAF p.V600E | TP53 truncation |
| Thyroid | Papillary Carcinoma | CCDC6-RET fusion | TP53 truncation |
| Uterus | Endometrial Stromal Sarcoma | JAZF1-SUZ12 fusion | CDKN2A loss |
| Uterus | Endometrial Stromal Sarcoma | YWHAE-NUTM2A fusion | 16q loss, CDKN2A loss, TP53 loss, RB1 loss |
| Uterus | Endometrial Stromal Sarcoma | ZC3H7B-BCOR fusion | 16q loss, CDKN2A loss, TP53 loss, RB1 loss |
| Uterus | Uterine Endometrioid Carcinoma | PTEN truncation, PIK3CA p.E542K p.E545K p.H1047R, ARID1A truncation, CTNNB1 p.S33A/C/F/Y p.S37A/F/Y p.T41A p.S45F | TP53 truncation |
| Uterus | Uterine Endometrioid Carcinoma | PTEN truncation, PIK3CA p.E542K p.E545K p.H1047R, ARID1A truncation, KRAS p.G12X | TP53 truncation |
| Uterus | Uterine Endometrioid Carcinoma | PTEN truncation, PIK3R1 truncation, ARID1A truncation | CTNNB1 p.S33A/C/F/Y p.S37A/F/Y p.T41A p.S45F, KRAS p.G12X, PPP2R1A p.P179L/R p.R183G/P/Q/W, TP53 truncation |

## Count of Profiles by Tissue Type

- Adrenal Gland: 2
- Biliary Tract: 8
- Bladder: 3
- Bone: 1
- Bowel: 9
- Brain: 13
- Breast: 8
- Esophagus: 3
- Kidney: 2
- Lung: 8
- Ovary: 6
- Pancreas: 5
- Peritoneum: 1
- Pleura: 1
- Prostate: 6
- Salivary Gland: 5
- Skin: 3
- Soft Tissue: 10
- Stomach: 8
- Thymus: 1
- Thyroid: 5
- Uterus: 6

## License

Copyright 2024 [Xcoo, Inc.][xcoo]

Licensed under the [GPLv3][gplv3].

[xcoo]: https://xcoo.jp
[gplv3]: https://www.gnu.org/licenses/gpl-3.0.html
